CRISPR Therapeutics (CRSP) CFO Prasad Raju makes bona fide gift of 750 shares

Rhea-AI Filing Summary

CRISPR Therapeutics AG Chief Financial Officer Prasad Raju reported a bona fide gift of 750 Common Shares on 2026-08-07. The transfer is classified as a disposition, and following the gift he reports 14,815 Common Shares held directly.

Insider Trade Summary

Net Seller: 750 shares

Net Sell 1 txn

Insider Prasad Raju

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Gift	Common Shares	750	$0.00	$0.00

Holdings After Transaction: Common Shares — 14,815 shares (Direct)

Key Figures

Shares gifted: 750 Common Shares Reported price per share: $0.00 Shares held after transaction: 14,815 Common Shares

3 metrics

Shares gifted 750 Common Shares Bona fide gift on 2026-08-07

Reported price per share $0.00 Price field for bona fide gift transaction

Shares held after transaction 14,815 Common Shares Direct ownership following the reported gift

Key Terms

Bona fide gift, Common Shares, Form 4

3 terms

Bona fide gift financial

"The transaction code description is listed as "Bona fide gift""

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

Common Shares financial

"The security title for the transaction is "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Form 4 regulatory

"Insider activity is disclosed on SEC Form 4 for this transaction"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 05:36 PM Accepted by SEC EDGAR 08/11/2026 - 05:35 PM Learn about SEC filing dates

FAQ

What did CRISPR Therapeutics (CRSP) CFO Prasad Raju report in this Form 4?

He reported a bona fide gift of 750 Common Shares of CRISPR Therapeutics AG on 2026-08-07, classified as a non-derivative disposition, leaving him with 14,815 Common Shares held directly.

How many CRISPR Therapeutics (CRSP) shares were transferred as a gift?

The filing shows a gift transfer of 750 Common Shares. The transaction price is reported as $0.00 per share, consistent with its characterization as a bona fide gift rather than a sale.

What are Prasad Raju’s CRISPR Therapeutics (CRSP) holdings after this transaction?

After the reported gift of 750 Common Shares, Prasad Raju’s directly held position is 14,815 Common Shares, as disclosed in the post-transaction ownership figure on the Form 4.

Was the CRISPR Therapeutics (CRSP) Form 4 transaction under a Rule 10b5-1 plan?

The Rule 10b5-1 checkbox is not marked as affirmative, and there is no footnote indicating a trading plan, so the reported bona fide gift is not identified as made under such a plan.

Did CRISPR Therapeutics (CRSP) CFO sell any shares in this Form 4?

No sales are reported. The Form 4 discloses only a bona fide gift of 750 Common Shares, with no purchase or sale transactions and no derivative exercises listed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Prasad Raju

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/07/2026		G		750	D	$0.00	14,815	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Elizabeth Ryland Waldinger, attorney-in-fact	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)